HUM
HumanaBAI scenario view
RankAlpha Sentiment CodexPost-earnings T+3The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
AI commentary
The earnings evidence is mixed-positive fundamentally but the immediate market reaction was negative, with the stock down about 6.4% from the July 28 close through July 31. No usable social coverage is present, and post-print analyst revision detail remains limited. Humana IR historical price lookup: https://humana.gcs-web.com/stock-information/historical-price-lookup
Evidence flagged
peer set is too generic or lacks enough direct operating comparators; later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence
AI events
Humana reported Q2 adjusted EPS of $7.61, a 91.2% insurance benefit ratio in line with guidance, reaffirmed FY2026 adjusted EPS of at least $9.00, 92.75% benefit-ratio guidance, and approximately 25% individual Medicare Advantage membership growth. [#SEC-8K-2026-07-29]
A recent secondary news headline reported an upgrade, but the packet does not provide a verified firm, rating, target, or estimate change. Treat this as a monitoring hook rather than confirmed rerating evidence.
Humana reported that its newly awarded statewide Illinois Medicaid managed-care contract is expected to go live in January 2027, expanding its Medicaid footprint. [#SEC-8K-2026-07-29]
Recommendation
No formal recommendation provided.

